Split Creek Capital LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Split Creek Capital LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$217K	Buy	+881	New	+$224K	0.21%	126

Other funds holding ALNY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Split Creek Capital LLC's ALNY Position: Q3 2026 in Review

Split Creek Capital LLC opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 881 shares worth $217K. The stake represents 0.21% of the portfolio and ranks #126 among its holdings.

328 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Split Creek Capital LLC held 881 shares of Alnylam Pharmaceuticals worth $217K as of Q3 2026.
Alnylam Pharmaceuticals was a new Split Creek Capital LLC position in Q3 2026.
Alnylam Pharmaceuticals made up 0.21% of Split Creek Capital LLC's portfolio in Q3 2026, its #126 holding.
328 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Split Creek Capital LLC's 13F filing for Q3 2026, filed 2 Nov 2026.